11. Effect of inclisiran on haematological and immunological biomarkers: A Pooled analysis of ORION-9, -10 and -11 trial data. (August 2021) Authors: Landmesser, U.; Conde, L. Garcia; Wright, R.S.; Raal, F.J.; Koenig, W.; Leiter, L.A.; Schwartz, G.G.; Kallend, D.G.; Lawrence, D.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 331(2021) Page Start: e37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Effect of SiC content on electrical, thermal and ablative properties of pressureless sintered ZrB2-based ultrahigh temperature ceramic composites. Issue 2 (February 2017) Authors: Mallik, Manab; Kailath, Ansu. J.; Ray, K.K.; Mitra, R. Journal: Journal of the European Ceramic Society Issue: Volume 37:Issue 2(2017) Page Start: 559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Effects of pitavastatin therapy on glucose, HBA1C and incidence of diabetes mellitus: A meta-analysis of randomized controlled clinical trials in non-diabetic individuals. Issue 1 (July 2015) Authors: Vallejo-Vaz, A.J.; Seshasai, S.R. Kondapally; Kurogi, K.; Nozue, T.; Sugiyama, S.; Tsimikas, S.; Yoshida, H.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 241:Issue 1(2015) Page Start: e143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Efficacy and Safety of Bempedoic Acid + Ezetimibe Fixed-Dose Combination in Patients at High CVD Risk and with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy. (August 2019) Authors: Ballantyne, C.; Laufs, U.; Ray, K.K.; Leiter, L.A.; Bays, H.E.; Goldberg, A.C.; Stroes, E.S.G.; MacDougall, D.; Zhao, X.; Catapano, A.L. Journal: Atherosclerosis Issue: Volume 287(2019) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: Analysis of pooled patient-level data from phase 3 clinical trials. (December 2020) Authors: Duell, P.B.; Banach, M.; Catapano, A.L.; Laufs, U.; Mancini, G.B.J.; Ray, K.K.; Bloedon, L.T.; Ye, Z.; Goldberg, A.C. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. Final results from the pan-European observational heymans study suggest a mismatch between guidelines and PCSK9i reimbursement criteria. (August 2022) Authors: Ray, K.K.; Bruckert, E.; Perrone-Filardi, P.; Ebenbichler, C.; Vogt, A.; Bridges, I.; Sibartie, M.; Dhalwani, N. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Global perspective of paediatric Familial Hypercholesterolaemia: Analysis from the EAS FHSC registry on over 11, 200 children and adolescents with heterozygous Familial Hypercholesterolaemia from 44 countries. (August 2022) Authors: Dharmayat, K.I.; Vallejo-Vaz, A.J.; Stevens, C.A.; Lyons, A.R.; Catapano, A.L.; Freiberger, T.; Hovingh, G.K.; Mata, P.; Santos, R.; Soran, H.; Watts, G.F.; Raal, F.J.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. Heterozygous familial hypercholesterolaemia in children: Preliminary analysis from the EAS FHSC global registry on over 7, 900 children with familial hypercholesterolaemia. (December 2020) Authors: Dharmayat, K.; Stevens, C.; Lyons, A.; Catapano, A.L.; Freiberger, T.; Hovingh, K.; Kastelein, J.J.; Mata, P.; Raal, F.J.; Santos, R.D.; Soran, H.; Watts, G.F.; Ray, K.K.; Vallejo-Vaz, A.J.; Behalf Of The Fhsc, X. On Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Identification, characteristics and management of adults with heterozygous Familial Hypercholesterolaemia in high and non-high income countries participating in the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). (August 2022) Authors: Vallejo-Vaz, A.J.; Stevens, C.A.; Dharmayat, K.I.; Lyons, A.R.; Brandts, J.; Freiberger, T.; Hovingh, G.K.; Kastelein, J.J.; Mata, P.; Raal, F.J.; Santos, R.; Soran, H.; Watts, G.F.; Catapano, A.L.; Ray, K.K. Journal: Atherosclerosis Issue: Volume 355(2022) Page Start: 15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Inclisiran reduces LDL-cholesterol independent of genotype in subjects with heterozygous familial hypercholesterolaemia. (December 2020) Authors: Raal, F.J.; Kallend, D.; Ray, K.K.; Turner, T.A.; Koenig, W.; Wright, R.S.; Wijngaard, P.L.; Curcio, D.; Jaros, M.J.; Leiter, L.A.; Landmesser, U.; Kastelein, J.J. Journal: Atherosclerosis Issue: Volume 315(2020) Page Start: e7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗